Literature DB >> 10894463

Lung models: strengths and limitations.

T B Martonen1, C J Musante, R A Segal, J D Schroeter, D Hwang, M A Dolovich, R Burton, R M Spencer, J S Fleming.   

Abstract

The most widely used particle dosimetry models are those proposed by the National Council on Radiation Protection, International Commission for Radiological Protection, and the Netherlands National Institute of Public Health and the Environment (the RIVM model). Those models have inherent problems that may be regarded as serious drawbacks: for example, they are not physiologically realistic. They ignore the presence and commensurate effects of naturally occurring structural elements of lungs (eg, cartilaginous rings, carinal ridges), which have been demonstrated to affect the motion of inhaled air. Most importantly, the surface structures have been shown to influence the trajectories of inhaled particles transported by air streams. Thus, the model presented herein by Martonen et al may be perhaps the most appropriate for human lung dosimetry. In its present form, the model's major "strengths" are that it could be used for diverse purposes in medical research and practice, including: to target the delivery of drugs for diseases of the respiratory tract (eg, cystic fibrosis, asthma, bronchogenic carcinoma); to selectively deposit drugs for systemic distribution (eg, insulin); to design clinical studies; to interpret scintigraphy data from human subject exposures; to determine laboratory conditions for animal testing (ie, extrapolation modeling); and to aid in aerosolized drug delivery to children (pediatric medicine). Based on our research, we have found very good agreement between the predictions of our model and the experimental data of Heyder et al, and therefore advocate its use in the clinical arena. In closing, we would note that for the simulations reported herein the data entered into our computer program were the actual conditions of the Heyder et al experiments. However, the deposition model is more versatile and can simulate many aerosol therapy scenarios. For example, the core model has many computer subroutines that can be enlisted to simulate the effects of aerosol polydispersity, aerosol hygroscopicity, patient ventilation, patient lung morphology, patient age, and patient airway disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894463

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Artificial neural network prediction of aerosol deposition in human lungs.

Authors:  Javed Nazir; David J Barlow; M Jayne Lawrence; Christopher J Richardson; Ian Shrubb
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 3.  In silico models of aerosol delivery to the respiratory tract - development and applications.

Authors:  P Worth Longest; Landon T Holbrook
Journal:  Adv Drug Deliv Rev       Date:  2011-05-27       Impact factor: 15.470

4.  Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.

Authors:  Ross L Walenga; P Worth Longest
Journal:  J Pharm Sci       Date:  2016-01-13       Impact factor: 3.534

5.  Recommendations for Simulating Microparticle Deposition at Conditions Similar to the Upper Airways with Two-Equation Turbulence Models.

Authors:  Karl Bass; P Worth Longest
Journal:  J Aerosol Sci       Date:  2018-02-21       Impact factor: 3.433

Review 6.  A framework for assessing risks to children from exposure to environmental agents.

Authors:  George Daston; Elaine Faustman; Gary Ginsberg; Penny Fenner-Crisp; Stephen Olin; Babasaheb Sonawane; James Bruckner; William Breslin; Tara J McLaughlin
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.